On June 11, Insilico Medicine fell 5.01% in regular trading, trading at 31.52 HKD/share, with trading volume of 24.78 million HKD. The decline marks the fourth consecutive session of over 5% losses as the company faces a convergence of negative catalysts.

On the news front, the cornerstone investors and employee restricted shares lock-up period is set to expire on June 29, with approximately 453 million shares facing unlock — representing 81.25% of total share capital. With the current price still carrying a premium over the IPO price, market concerns over concentrated selling pressure continue to intensify. Fundamentally, the company reported revenue declining 34.48% year-over-year with a net loss attributable to shareholders of USD 352 million, leaving no earnings inflection point in sight.

Within the Life Sciences Tools and Services sector, the overall tone remained soft. Among peers, WUXI XDC fell 3.45%, XtalPi fell 2.73%, and WUXI BIO fell 0.81%, with sector-wide weakness further dampening sentiment around Insilico Medicine.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)